The enhanced response to AS was reduced to T72 h baseline (that is, no AS control) using neutralizing antibodies to EGFR, which is consistent with the aberrant activation of EGFR pathway in a majority of HNSCC and other cancers of epithelial origin27, 29. This evidence concerns the gene EGFR and cancer.